I too have multiple myeloma. I’ve done RVD, a stem cell transplant and am on one of the new oral meds for maintenance. Six years now since I was first diagnosed. I have watched some of my markers gradually climb over the last 6 years but since seriously changing my eating habits, ...
CD133 is widely used as a marker to identify CRC stem cells and endothelial progenitor cells [73]. It can also be used to predict tumor progression, patient survival and chemoradiotherapy resistance in CRC [74,75] and is one of the most well-characterized markers of cancer stem cells (CSCs...
et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165, 6037–6046 (2000). Article CAS PubMed Google Scholar Siegal, F. P. et al. The nature of the principal type 1 interferon-producing cells in ...
Fig. 5: Expression levels of immune markers on LOAd-infected multiple myeloma cells. Cells were infected with 100 MOI of LOAd(−), LOAd700, and LOAd703 or left uninfected, cultured for 48 h and analyzed by flow cytometry for the expression of HLA-ABC (a), HLA-DR (b), CD86 (c...
First, priority should be given to the appropriate population for immunotherapy before treatment. The type and number of tumor markers, even the presence of PBRM1 gene defects [86,87] and intestinal flora, are tested to determine whether the patient was a suitable individual for treatment. Then,...
One method for identifying HRD is using patterns of genomic aberrations known as ‘mutational signatures’ [14]. These signatures act as markers of prior mutagenic events and features, and identifying them within the cancer genome can highlight the driving forces behind the development of a given ...
Since the cancer stem cell concept has been widely accepted, several strategies have been proposed to attack cancer stem cells (CSC). Accordingly, stem cell markers are now preferred therapeutic targets. However, the problem of tumor specificity has not
Shimamoto et al [6] reviewed 165 cases with IgD MM and on multivariate analysis showed that λ light-chains and white blood cell count > 7 × 109 where adverse prognostic markers. In our series we registered in 11 out of 17 patients (64%) the presence of λ light-chains and Bence-...
et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165, 6037–6046 (2000). Article CAS PubMed Google Scholar Haniffa, M. et al. Human tissues contain CD141hi cross-presenting dendritic cells with ...
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica 102, 562–572 (2017). Article CAS PubMed PubMed Central Google Scholar Chong, E. A. et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T ...